Gardasil News and Research

RSS

Gardasil is a vaccine that prevents the types of genital human papillomavirus (HPV) that cause most cases of cervical cancer and genital warts. The vaccine, Gardasil, is given in three shots over six-months. The vaccine is routinely recommended for 11 and 12 year old girls. It is also recommended for girls and women age 13 through 26 who have not yet been vaccinated or completed the vaccine series.

Parental perceptions pose major barrier to acceptance of HPV vaccination

A Mayo Clinic physician and two other pediatric experts say that parental perceptions pose a major barrier to acceptance of human papillomavirus (HPV) vaccination — and that many of those perceptions are wrong.

22 Oct 2013

New article in Preventive Medicine journal explores suspicions about sexual promiscuity, vaccine safety

Suspicions about sexual promiscuity and vaccine safety are explored in an article in the November issue of the journal Preventive Medicine, which dedicates a section of that issue to research concerning the human papillomavirus.

18 Oct 2013

Researchers find no serious adverse effects of HPV vaccine in girls

Researchers at Karolinska Institutet in Sweden and their Danish colleagues have monitored HPV-vaccinated girls via patient data registries in order to examine the incidence of a wide range of diseases and thus determine if there are any serious adverse effects of the vaccine. Their results show no significant increase of the examined diseases in the vaccinated girls relative to their unvaccinated peers.

10 Oct 2013

Emphasizing STD prevention will persuade young women to get HPV vaccine, study suggests

The HPV vaccine can prevent both cervical cancer and a nasty sexually transmitted disease in women.

3 May 2013

Research: HIV women infected with HPV are not protected by current vaccines

Women with HIV acquire cancer-causing forms of the human papillomavirus (HPV) that are not included in the current HPV vaccines Gardasil and Cervarix, according to new research from Fox Chase Cancer Center being presented at the AACR Annual Meeting 2013 on Sunday, April 7.

8 Apr 2013

GAVI Alliance to fund HPV immunization projects in 8 countries

The GAVI Alliance "is to help protect more than 180,000 girls in eight countries across Africa and Asia from cervical cancer by funding immunization projects with vaccines from Merck and GlaxoSmithKline," Reuters reports in an article examining the group's efforts to vaccinate young women with Merck's Gardasil and GSK's Cervarix, "the world's only two approved shots designed to protect against the sexually transmitted human papillomavirus (HPV) that causes the vast majority of cervical cancer cases."

5 Feb 2013

Merck full-year 2012 worldwide sales decrease 2% to $47.3 billion

Merck, known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2012.

1 Feb 2013

Scientists figure out how to dodge HPV-triggered cancers by vaccination

In 2009, more than 30,000 people in the U.S. learned they had cancer linked to the human papillomavirus, or HPV. This virus is best known for causing cervical cancer, but it's also the culprit behind many cancers of the mouth, throat, anus, and genitals. Unlike many forms of cancer, for which we lack the knowledge and tools to prevent, scientists have figured out how to dodge HPV-triggered cancers — by HPV vaccination.

19 Jan 2013

Virginia Women's Center to participate in new HPV and cervical cancer vaccine clinical trial

Virginia Women's Center has been selected to participate in a nationwide clinical trial, one that will ultimately hope to prevent the human papillomavirus virus (HPV) from progressing into cervical cancer and treat women who have HPV and the precancerous lesions associated with it. The Richmond-area OB-GYN practice has participated in over 50 clinical research studies since 1997, all of which have contributed to the future of safe and effective medicine for women.

4 Dec 2012

Taking technology from the lab to the patient: SMART Arm™: Hand of hope for stroke survivors

Creating a viable commercial product from its beginnings as a research concept through to a final product patients can use is a long, difficult and often expensive process. However, as David Henderson, the Managing Director of UniQuest, one of the leading technology transfer companies in the Asia Pacific region explains, a focus on patient needs is vital for developing a successful product.

15 Oct 2012

Gardasil does not increase sexual activity in girls

The human papillomavirus (HPV) vaccine known as Gardasil is not associated with an increase in pregnancy, sexually transmitted infections, or contraceptive counseling, according to a Kaiser Permanente study published online today in the journal Pediatrics.

15 Oct 2012

Bivalent HPV vaccine has cross-protective effect, but could wane over time

The bivalent vaccine for human papillomavirus types 16 and 18 appears to be more efficacious against outcomes associated with nonvaccine types 31, 33, and 45 than its quadrivalent counterpart, show results of a systematic review and meta-analysis.

5 Oct 2012

Paper provides overview on preventing invasive cervical cancer

Researchers at Moffitt Cancer Center and colleagues at the University of South Florida and The Ohio State University have published a paper in the September issue of Cancer Epidemiology, Biomarkers & Prevention that provides an overview on preventing invasive cervical cancer.

28 Sep 2012

Uganda launches vaccination campaign against cervical cancer

"The government of Uganda has launched a vaccination campaign against cervical cancer -- the most common type of cancer among Ugandan women -- but there are already fears a nationwide rollout might be jeopardized by lack of funds," IRIN reports.

7 Sep 2012

Pathologist identifies HPV DNA fragments in post-mortem samples after Gardasil vaccination

According to Norma Erickson, President of SaneVax Inc., testimony provided for a coroner's inquest into the death of Jasmine Renata in New Zealand by Dr. Sin Hang Lee, a pathologist on the medical staff at Connecticut's Milford Hospital, revealed the discovery of HPV DNA fragments in post-mortem samples 6 months after Gardasil vaccination.

9 Aug 2012

Roundup: Ore. Gov. suggests malpractice reform; Mass. Gov. proposes new scrutiny for health care providers; Texas has offered HPV vaccine since 2007

The state can cut health care costs and reduce the number of medical-related lawsuits by requiring earlier notification of injuries as well as pretrial mediation, according to a recommendation Gov. John Kitzhaber issued Wednesday. The product of closed-door talks between representatives of interest groups including the Oregon Medical Association and the Oregon Trial Lawyers Association, Kitzhaber's recommendation now goes to a work group including lawmakers, a trial lawyer and doctor that begins public meetings next week.

27 Jul 2012

Allied Healthcare increases stake in Coridon to over 44%

Allied Healthcare Group (ASX: AHZ) announced today that post the recent capital raising it has invested a further $1 million into Coridon, increasing its holding in the company to 44.4%. Allied has increased its investment in Coridon as the Company progresses towards its Phase I study for a herpes vaccine and makes further progress on its HPV therapeutic vaccine program.

26 Apr 2012

Canadian docs recommend HPV vaccine for boys

Girls have had access to free HPV vaccinations for five years - administered to protect them against cervical cancer - and this week, the Canadian Cancer Advocacy Coalition called on provincial governments to pay for the vaccine for boys as well. In January, the National Advisory Committee on Immunization recommended HPV vaccination for males aged nine to 25.

16 Apr 2012

Young girls face increased risk of side effects after Gardasil vaccination

Younger girls are more likely than adult women to report side effects after receiving Gardasil, the human papillomavirus vaccine.

4 Apr 2012

HPV vaccine recommended for boys

The American Academy of Pediatrics has recommended boys - not just girls - be vaccinated against HPV, though questions about its cost-effectiveness remain.

29 Feb 2012